Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma

Por um escritor misterioso
Last updated 10 novembro 2024
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Dupilumab demonstrates long-term safety, efficacy among children
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Dupilumab demonstrates long-term safety, efficacy among children
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Efficacy of dupilumab in asthma.
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Dupixent® reduces rate of severe asthma attacks in children, finds
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Efficacy and safety of dupilumab with concomitant topical
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Frontiers Dupilumab efficacy and safety in patients with
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Dupilumab Safe, Effective in Kids With Moderate-to-Severe Asthma
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Dupilumab pharmacokinetics and effect on type 2 biomarkers in
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
New Drug a Good Treatment Option for Severe Asthma in Kids
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Consider Referring Patients to a DUPIXENT® (dupilumab) Eczema
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Full article: A 52-week multicenter retrospective real-world study

© 2014-2024 progresstn.com. All rights reserved.